---
category: news
title: "Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter"
excerpt: "Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromicâ€™s AI platform. HOUSTON-- ( BUSINESS WIRE )--Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics,"
publishedDateTime: 2021-05-24T15:55:00Z
originalUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
webUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
type: article

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

secured: "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;CI1Chc6UCWrbyBdv14dDnw=="
---

